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Abstract
Background: Siglecs-11 and -16 are members of the sialic acid recognizing Ig-like lectin family, and expressed in
same cells. Siglec-11 functions as an inhibitory receptor, whereas Siglec-16 exhibits activating properties. In humans,
SIGLEC11 and SIGLEC16 gene sequences are extremely similar in the region encoding the extracellular domain due
to gene conversions. Human SIGLEC11 was converted by the nonfunctional SIGLEC16P allele, and the converted
SIGLEC11 allele became fixed in humans, possibly because it provides novel neuroprotective functions in brain
microglia. However, the detailed evolutionary history of SIGLEC11 and SIGLEC16 in other primates remains unclear.
Results: We analyzed SIGLEC11 and SIGLEC16 gene sequences of multiple primate species, and examined glycan
binding profiles of these Siglecs. The phylogenetic tree demonstrated that gene conversions between SIGLEC11
and SIGLEC16 occurred in the region including the exon encoding the sialic acid binding domain in every primate
examined. Functional assays showed that glycan binding preference is similar between Siglec-11 and Siglec-16 in
all analyzed hominid species. Taken together with the fact that Siglec-11 and Siglec-16 are expressed in the same
cells, Siglec-11 and Siglec-16 are regarded as paired receptors that have maintained similar ligand binding
preferences via gene conversions. Relaxed functional constraints were detected on the SIGLEC11 and SIGLEC16
exons that underwent gene conversions, possibly contributing to the evolutionary acceptance of repeated gene
conversions. The frequency of nonfunctional SIGLEC16P alleles is much higher than that of SIGLEC16 alleles in every
human population.
Conclusions: Our findings indicate that Siglec-11 and Siglec-16 have been maintained as paired receptors by
repeated gene conversions under relaxed functional constraints in the primate lineage. The high prevalence of the
nonfunctional SIGLEC16P allele and the fixation of the converted SIGLEC11 imply that the loss of Siglec-16 and the
gain of Siglec-11 in microglia might have been favored during the evolution of human lineage.
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Background
Sialic acids are a family of nine-carbon sugars that are
found at the outer end of glycan chains on the cell surface
and secreted molecules in the deuterostome lineage, and
play important roles as recognition components in cell–
cell communication and host–pathogen interactions [1–3].
Siglecs (sialic acid-binding immunoglobulin superfamily
lectins) are type I transmembrane proteins that recognize
sialic acids and are mostly expressed in the cells in-
volved in immunity [4–7]. Their extracellular regions
consist of one V-set immunoglobulin-like domain (V-
set domain) that is essential for sialic acid recognition,
and variable numbers of C2-set immunoglobulin-like
domains. Many Siglecs have signaling motifs in their
cytoplasmic tail or transmembrane domain and induce
signal transduction in cells.
Siglec-11 has inhibitory signaling motifs (immunore-
ceptor tyrosine-based inhibitory motifs: ITIMs) in its
cytoplasmic tail and functions as a receptor that inhibits
cell functions by recognizing sialic acids [8]. On the
other hand, Siglec-16 has no signaling motifs, but
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activates cell functions by association with an adaptor
molecule that contains immunoreceptor tyrosine-based
activating motif (ITAM) [9]. Both Siglec-11 and Siglec-
16 are expressed on macrophages, and probably regulate
cell signaling [8, 9]. SIGLEC11 and SIGLEC16 genes are
found in head-to-head orientation about 9 kb apart in
the human genome [8, 9]. The sequences of the ~3-kb
genomic regions containing exons encoding N-terminal
region (V-set domain and C2-set domains) in these two
genes are highly similar. This evolutionary kinship sug-
gests that these Siglec genes originally emerged via a
gene duplication event [8, 9]. Interestingly, the human
SIGLEC16 locus has functional and nonfunctional alleles
within populations [9, 10]. The nonfunctional allele
(SIGLEC16P allele) has a 4 base pair deletion in exon 2,
and produces a very short protein (Siglec-16P), if any,
lacking a transmembrane domain. We previously re-
ported that SIGLEC16P converted the SIGLEC11 gene
about 1 million years ago (MYA) in the human lineage
(SIGLEC16P→SIGLEC11 gene conversion)[10], and the
human SIGLEC11 gene came to be expressed in brain
microglia [11]. In addition, immunostaining using anti-
Siglec-16 antibody suggested that human Siglec-16 is
also expressed in brain microglia [9]. The human-
specific SIGLEC16P→SIGLEC11 gene conversion in-
cluded ~240 bp of 5′ untranslated region of the gene
[11], and a GATA-1-binding sequence, which is known
as a repressor of BACE1 transcription in rat microglial
cells [12], is modified by the SIGLEC16P→SIGLEC11
gene conversion ([10]; see Additional file 1: Figure S1).
Thus, it is possible that the brain expression of human
Siglec-11 emerged via the SIGLEC16P→SIGLEC11 gene
conversion. The SIGLEC16P→SIGLEC11 gene conver-
sion is an example of a pseudogene (a nonfunctional al-
lele) contributing to the evolution of a functional gene.
Surprisingly, SIGLEC16P has persisted for over 3 million
years (MYR) in the human lineage. Three hypotheses
have been proposed to explain this [7, 10]. One is a
gradual phasing out of Siglec-16 [7]. Siglec-11 shows
neuroprotective effects such as inhibition of the produc-
tion of proinflammatory mediators, and plays an import-
ant role in the immune function of microglia [13].
Siglec-16 activates immune and inflammatory responses
in the brain microglia and may counteract the neuropro-
tective effect of Siglec-11. This unfavorable role of
Siglec-16 in the brain might have resulted in the elimin-
ation of Siglec-16 in the human lineage. A second
hypothesis proposes a balance between pathogenic pres-
sure to retain Siglec-16 within populations and the
elimination of Siglec-16 driven by its detrimental effects
on immune activation [7]. The last hypothesis is hitch-
hiking on the adjacent SIGLEC11 gene [10]. After the
SIGLEC16P→SIGLEC11 gene conversion, the converted
SIGLEC11 gene was fixed in human populations. Since
SIGLEC11 and SIGLEC16 loci are located close together
in the genome, this fixation might have driven the high
frequency of SIGLEC16P alleles in human populations.
These are intriguing hypotheses, but need to be exam-
ined by further studies.
Siglec-11 and Siglec-16 have coevolved via gene con-
versions in the human lineage. However, the evolution-
ary role of observed human-specific changes of Siglec-11
and Siglec-16 is still unknown. To gain deeper insight
into the evolutionary relationship between Siglec-11 and
Siglec-16, we analyzed the sequences of the SIGLEC11
and SIGLEC16 genes not only from human but also
from nonhuman primates. We also examined the glycan
binding properties of Siglec-11 and Siglec-16 to deter-
mine the functional role of gene conversion between
Siglec-11 and Siglec-16 because the converted region in-
cludes the exon encoding the sialic acid binding domain
(i.e., V-set domain).
Results
Gene conversions between SIGLEC11 and SIGLEC16 in
each primate lineage
The genomic region including the first eight exons and a
region upstream of the gene is similar between the hu-
man SIGLEC11 and SIGLEC16 genes (Fig. 1). A
(GAAT)n tract is found at the 5′ boundary of these
similar regions, and the 3′ boundary is assumed to be
around the 3′ end of exon 8 (see Additional file 1: Figure
S1). In the human lineage, gene conversions between
SIGLEC11 and SIGLEC16 occurred in a ~2-kb part of
this region, which contains a region upstream of the
gene and the exon encoding the sialic acid binding do-
main (V-set domain) [10, 11]. To determine whether
gene conversions have occurred in nonhuman primates,
we examined the genomic sequences of chimpanzee,
gorilla, gibbon, and baboon. Apes and baboon have both
SIGLEC11 and SIGLEC16 genes. On the other hand,
only the SIGLEC11 gene is identified in the public data-
bases of the marmoset genome and squirrel monkey
genome (data not shown). Thus, it seems that SIGLEC16
emerged from SIGLEC11 by gene duplication before the
emergence of the common ancestor of Old World mon-
keys and hominoids. The (GAAT)n tract located at the
5′ boundary of the similar regions is conserved in all
species examined, and was thus probably involved in this
duplication event. On the other hand, there is no defin-
ing sequence motif at the 3′ boundary in all species ex-
amined. A frameshift mutation and a large deletion are
found in baboon SIGLEC11 and SIGLEC16, respectively
(Additional file 1: Figure S1).
A sliding window plot (Fig. 1b) illustrates that the gen-
omic region containing a region upstream of the gene
and the first five exons (region A and A’ in SIGLEC11
and SIGLEC16, respectively) shows high sequence
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identity between SIGLEC11 and SIGLEC16 genes in each
species: 99.3% in the human, 98.2% in the chimpanzee,
98.5% in the gorilla, 97.8% in the gibbon, and 96.9% in
the baboon. The rest of the similar regions (designated B
and B’ in SIGLEC11 and SIGLEC16, respectively) show
lower identity in all species (93.1% in the human, 93.4%
in the chimpanzee, 93.0% in the gorilla, 92.7% in the gib-
bon, and 87.6% in the baboon). Estimated upstream and
downstream boundaries of A/A’ regions differ among
the species, and there is no sequence motif signifying
these boundaries (see Fig. 1b and Additional file 1:
Figure S1).
a
b
Fig. 1 Comparison of the SIGLEC11 and SIGLEC16 genes. a Gene structures of SIGLEC11 and SIGLEC16. Exons of SIGLEC11 and SIGLEC16 are
represented by solid and open boxes, respectively. The regions with similarity between SIGLEC11 and SIGLEC16 are indicated with a light shadow
(A/A’) and a dark shadow (B/B’). b Sliding window analysis of the conservation profile of SIGLEC11 versus SIGLEC16 (window size 20 bp; step size 1
bp). The ~2-kb genomic region shows consistently high sequence identity (97%–99%) between SIGLEC11 and SIGLEC16 in every species, and is
designated the Ac/Ac’ region. On the other hand, the ~400-bp genomic region shows consistently lower identity in the similar region of every
species, and is designated the Bc/Bc’ region
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The ~2-kb genomic region (designated Ac and Ac’ in
SIGLEC11 and SIGLEC16, respectively) in the A/A’ re-
gion shows high sequence identity (97%–99%) consist-
ently in every species (Fig. 1b). As shown in Fig. 2a, a
phylogenetic tree of the Ac/Ac’ region shows that the
SIGLEC11 and SIGLEC16 genes in each species form a
cluster, but do not with their respective orthologs in
other species. On the other hand, the ~400-bp genomic
region (designated Bc and Bc’ in SIGLEC11 and
SIGLEC16, respectively) in the B/B’ region contains the
3′ part of exon 7 and most of exon 8 and shows lower
identity consistently in every species (Fig. 1b). The
topology of the phylogenetic tree constructed from the
Bc/Bc’ region matches expectations given the paralogous
relationship between the SIGLEC11 and SIGLEC16
genes (Fig. 2b). These phylogenetic trees suggest that
gene conversions occurred in the A/A’ regions of every
primate species.
It is worth noting that the current sequence compari-
son among primate SIGLEC11 and SIGLEC16 provides
further evidence that the GATA-1-binding sequence,
which is assumed to be involved in human-specific brain
expression of Siglec-11 [10], is modified only in the hu-
man genes (see Additional file 1: Figure S1). This
strengthens the speculation that the SIGLEC16P→SI-
GLEC11 gene conversion resulted in the gain of human-
specific brain expression of Siglec-11.
Timing of gene conversions in each primate
We calculated the timing of the gene conversions in the
nonhuman primates using noncoding parts of the Ac/
Ac’ region. Relative rate tests were performed based on
the tree of noncoding parts of the Ac/Ac’ region
(Additional file 2: Figure S2), and showed that a rate
constancy can be assumed between SIGLEC11 and
SIGLEC16 genes in chimpanzee, gorilla, and gibbon
lineages. The timing (T) of gene conversion can be
roughly estimated by T = d/2λ, where d is the genetic
distance between the SIGLEC11 and SIGLEC16 genes of
each species and λ is the neutral mutation rate of the
genomic region containing the SIGLEC11 locus [(1.4 ±
0.1) × 10-9/site/year; [10]]. We estimated the timing of
Fig. 2 Phylogenetic relationships of (a) the Ac/Ac’ region and (b) the Bc/Bc’ region of SIGLEC11 and SIGLEC16. Numbers on the phylogenetic tree
represent bootstrap values based on 1000 replications. Hsa, Homo sapiens; Ptr, Pan troglodytes; Ggo, Gorilla gorilla; Hla, Hylobates lar; Pan, Papio
anubis; Cja, Callithrix jacchus
Hayakawa et al. BMC Evolutionary Biology  (2017) 17:228 Page 4 of 11
most recent gene conversions in chimpanzee, gorilla,
and gibbon lineages as 4.4 ± 1.5 MYR, 6.9 ± 1.9
MYR, and 8.4 ± 2.0 MYR, respectively. The prelimin-
ary phylogenetic analysis using the partial sequence of
bonobo shows that gene conversions in the lineage of
the genus Pan occurred before the divergence of
chimpanzee and bonobo (see Additional file 2: Figure
S2). Since chimpanzee and bonobo diverged ~2 MYA
[14], the calculated timing (4.4 ± 1.5 MYR) of gene
conversion in the Pan lineage is consistent with the
tree topology shown in Figure S2. The noncoding part
(~800 bp) from the Ac/Ac’ region is short, and the
current calculation cannot avoid the ambiguity result-
ing from the use of a very short noncoding part.
However, the obtained timing results should be help-
ful to consider the frequency of gene conversions in
the nonhuman primate lineage, and suggests that the
frequency of gene conversion is not so high in each
nonhuman primate lineage.
Glycan binding properties of Siglec-11 and Siglec-16
The A/A’ region contains the exon encoding the sialic
acid binding domain (see Additional file 3: Figure S3). It
is thus expected that sequence homogenization by gene
conversions has maintained similar glycan binding prop-
erties between Siglec-11 and Siglec-16. To test this
hypothesis, we performed glycan binding assays using
soluble recombinant proteins that include the V-set do-
main and the adjacent C2-set domain of Siglecs linked
to the Fc portion of human immunoglobulin G (Siglec-
Fc). We prepared recombinant human, chimpanzee, and
gorilla Siglec-11-Fc and Siglec-16-Fc proteins, and tested
their binding to glycan-polymer probes. Binding prefer-
ences (based on the order of binding signal intensity to
the probes) were very similar between Siglec-11 and
Siglec-16 in each species as expected, but were also
largely conserved across human and great ape species
(Fig. 3a). We also used a glycan microarray to analyze
ligand specificity in greater detail, and tested whether
Siglec-11 and Siglec-16 of the same species show more
similar binding patterns compared with their respective
orthologs in other species (Fig. 3b). Siglec-11 and Siglec-
16 from the three species showed similar binding pat-
terns, distinct from Siglec-7 and Siglec-9. However, the
branch topology of the subtree for Siglec-11 and Siglec-
16 did not match that of the molecular phylogenetic tree
based on the DNA sequences (see Fig. 2a). Taken
together, it is reasonable to think that sequence
homogenization by gene conversion has maintained
similarity in the glycan binding preference between
Siglec-11 and Siglec-16 along the primate lineage, but
not a strict identity in the glycan binding preference
between them in each species.
Relaxed evolution of Siglec-11/Siglec-16 paired receptors
To gain more insight into the evolutionary background
of frequent gene conversion between SIGLEC11 and
SIGLEC16, we examined functional constraints on the
exons of genomic regions (Ac/Ac’ region) that under-
went gene conversion in every primate species by the
comparison of branch length between the tree of neutral
sites (introns and synonymous sites in exons) and that of
nonsynonymous sites. A significant difference between
nonsynonymous and neutral substitutions per site is
found in only three branches: first, the branch leading to
the gorilla SIGLEC11 gene; second, the branch leading
to baboon SIGLEC11; and third, the branch leading to
baboon genes (Additional file 4: Figure S4). Our analysis
has a limitation due to the use of short region (~2 kb),
but suggests the relaxation of functional constraints on
the exons of the Ac/Ac’ regions of both SIGLEC11 and
SIGLEC16 genes in the Hominoidea lineage. It is also
possible that this relaxed functional constraint might be
related to evolutionary acceptance of repeated gene con-
versions in the A/A’ region, contributing to the mainten-
ance of Siglec-11 and Siglec-16 as paired receptors.
Dimorphism of Siglec-11/Siglec-16 paired receptors in
humans
Immune cell receptors that show significant homology
within their extracellular domains and overlapping ex-
pression patterns, but opposite roles in signal transduc-
tion, are called paired receptors. They are proposed to
be involved in the fine-tuning of immune responses via
a balance in the ligand binding between the activating
and inhibitory members of the pair [15]. Siglec-11 and
Siglec-16 are inhibitory and activating receptors, respect-
ively, and expressed in the same cells such as macro-
phages [8, 9]. Moreover, the glycan binding preferences
are very similar between Siglec-11 and Siglec-16, as
demonstrated above (Fig. 3). Therefore, Siglec-11 and
Siglec-16 are regarded as paired receptors.
Since human SIGLEC16P alleles have a 4 base pair de-
letion in exon 2 and produce a truncated protein lacking
a transmembrane domain, human Siglec-11 completely
lost its partner as a paired receptor in individuals having
only SIGLEC16P alleles. We previously reported that the
frequency of SIGLEC16P is high in every human popula-
tion [10]. We also updated the frequency of SIGLEC16P
alleles using recent data from the 1000 Genomes Project
(http://browser.1000genomes.org/index.html) (Additional
file 5: Figure S5), based on the allele frequencies of SNPs
(rs66855472, rs16981577, rs35248548, rs12975261, rs1297
5940, rs12978378, rs12978610, rs12609492, rs12609509,
rs12611411, rs12609811, rs12984584, rs34038717, rs129
71775, and rs12985533) that were in perfect linkage dis-
equilibrium with SIGLEC16/SIGLEC16P polymorphism in
the haplotypes identified in our previous work (see Fig. 7c
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Fig. 3 Binding of glycan probes by recombinant Siglec-11 and Siglec-16 from human, chimpanzee, and gorilla. Glycan binding assay was carried
out as described in Materials and Methods. a Binding of synthetic glycan-polymer probes by Siglecs on solid phase. All recombinant Siglec-Fc
proteins tested in the assay showed similar glycan binding preferences, in that the signal intensity of glycan probe binding was as follows:
Neu5Acα2-6GalNAc > Neu5Acα2-8Neu5Ac > Neu5Acα2-6Galβ1-4Glc > Neu5Acα2-3Galβ1-4Glc. Wells coated with human TREM-1 (TREM1) or
without any recombinant protein (None) showed negligible binding to these glycan probes and thus were appropriate as negative controls.
Binding assays were carried out in triplicate wells for each combination of protein and probe. The experiment was repeated twice with consistent
results, and a representative result is shown. Error bar represents standard error of the mean. b Binding of Siglecs to glycan microarray. Binding signal
intensities were normalized by the root mean square method, and are represented by a heat map (higher color intensity = strong binding). Human
Siglec-7 and Siglec-9 were included in the analysis as outgroups. Two different concentrations (20 or 40 μg/ml) of each Siglec-Fc were used in the
binding analysis, and gave consistent binding patterns. Trees generated by unsupervised hierarchical clustering of Siglecs (top) and glycans (left), and
the glycan structures (right) are shown beside the heat map. Siglec-11 and Siglec-16 from three species are clustered together
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in Wang et al. [10]). These SNPs show the complete agree-
ment in the minor allele frequency with each other in all
26 human populations from the 1000 genome project with
the exception of seven SNPs showing unique frequencies
in several populations (four populations at rs66855472,
two populations at rs12978378, and one population at each
rs12978610, rs12611411, rs12609811, rs12971775, and
rs12985533) (Additional file 6: Table S1). Since the number
of individuals in each population is the same between the
SNPs, the discrepancy in frequencies in several populations
at the seven SNPs is likely due to recombination or geno-
typing error. Data for all of these SNP sites indicate that
the frequency of SIGLEC16P alleles (65%–91%) is much
higher than that of SIGLEC16 alleles in every human popu-
lation (Additional file 5: Figure S5 and Additional file 6:
Table S1). In modern human populations, over a half of
individuals have only SIGLEC16P alleles.
Discussion
Our study demonstrated that, in addition to the SIGLE-
C16P→SIGLEC11 gene conversion in the human lineage
[10, 11], the gene conversion between SIGLEC11 and
SIGLEC16 has occurred in each nonhuman primate
lineage. The region converted in common in all primate
species contains first five exons of SIGLEC11 and first
four exons of SIGLEC16 (see Fig. 1b), and is smaller
than the region that was used to detect the SIGLE-
C16P→SIGLEC11 gene conversion by the comparison
between the human and chimpanzee sequences [10, 11].
These exons of the two SIGLEC genes have undergone
repeated gene conversion along the primate lineage. Se-
quence homogenization by gene conversion appears to
have maintained the glycan binding preferences of
Siglec-11/Siglec-16 paired receptors similar. It is thus
possible to conclude that sequence homogenization be-
tween first five exons of SIGLEC11 and first four exons
of SIGLEC16 are essential to maintain Siglec-11 and
Siglec-16 as paired receptors in the primate lineage. The
frequency of gene conversions is inversely proportional
to the distance between the interacting sequences in cis
[16]. The A region of SIGLEC11 gene is located about 9
kb apart from A’ of SIGLEC16 gene. This proximity of
genes seems to be an important factor that has caused
frequent gene conversions in the evolution of Siglec-11/
Siglec-16 paired receptors.
The sliding window analysis indicates that actual con-
verted regions are fragmented in the A/A’ region of each
primate (Fig. 1b). In addition, the gene conversion oc-
curred ~1 MYA in the human lineage [10], and the gene
conversion have not occurred during at least 2 MYR in
the Pan lineage. These suggest that some degree of se-
quence differences between the SIGLEC11 and SIGLEC16
genes has been accepted in each species. This is consistent
with our observation that Siglec-11 and Siglec-16 did not
show a strict identity in the glycan binding preferences
(see Fig. 3), and thus may imply that such strict identity is
not essential for them to function as paired receptors.
Some pathogens engage inhibitory Siglecs, and attenu-
ate immune responses. We proposed activating Siglecs
may have emerged as a counter-measure against patho-
gens that exploit inhibitory counterparts [17]. The
Siglec-11/Siglec-16 paired receptors might have emerged
and have been maintained under the interaction with
pathogens that target macrophage (see below) along the
primate lineage. The relaxation of functional constraints
was deduced on the exons of the Ac/Ac’ regions of both
SIGLEC11 and SIGLEC16 genes in the Catarrhini
lineage. This relaxation of functional constraint might
have contributed to an arms race against pathogens, by
allowing a rapid functional evolution of these Siglec pro-
teins. Interestingly, in addition to human Siglec-11 and
Siglec-16 for which expression in the brain emerged,
chimpanzee and gorilla Siglecs-11 and -16 show binding
to Neu5Acα2-8Neu5Ac (α2-8-linked sialic acids), a
glycan structure that is enriched in the brain (Fig. 3).
The relaxation of functional constraint might have
contributed to the acquisition of binding to α2-8-linked
sialic acids before Siglec-11 and Siglec-16 started to be
expressed in the brain in the human lineage, namely, ex-
aptation, for binding to brain sialic acids, and enabled
Siglec-11 and Siglec-16 to participate as functional re-
ceptors in brain immunity.
If Siglec-16 is functionally essential for human biology,
the SIGLEC16P allele should be deleterious in human
evolution. The possible functional importance of Siglec-
16 in human immunity has been suggested by our recent
study demonstrating its interaction with the human-
specific pathogen Escherichia coli K1 that produces a
capsular polysaccharide made of α2-8-linked sialic acids,
which is a perfect mimic of the preferred ligand of
Siglec-11/Siglec-16 paired receptors [18]. It is therefore
reasonable to assume that Siglec-16 is involved in the
host defense against some bacteria. However, the
SIGLEC16P allele has persisted for over 3 MYR, and
shows very high frequency in human populations. The
presence of functional Siglec-16 protein may be deleteri-
ous under certain circumstances while being beneficial
under others, as is the case for Siglec-14 [19, 20].
Only humans have been shown to have both Siglec-11
and Siglec-16 as paired receptors in the brain microglia.
Human Siglec-11 came to be expressed in the brain
microglia even after the SIGLEC16P allele had emerged,
which indicates that the human had Siglec-16 and
Siglec-16P in brain microglia before Siglec-11 gained
brain expression. Siglec-11 shows neuroprotective effects
such as inhibition of the production of proinflammatory
mediators, and likely plays an important role as an in-
hibitory receptor in the immune function of microglia
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[13]. Siglec-16 activates immune and inflammatory re-
sponses in the brain microglia, and the activation of
brain microglia is associated with mental disorders such
as schizophrenia [21]. It is thus tempting to speculate
that the partial elimination of Siglec-16 already occurred
to reduce the unnecessary activation of brain microglia
before the gain of Siglec-11 in the brain microglia, and
Siglec-11 then came to be expressed in the brain micro-
glia, which led to the further suppression of this
unnecessary activation even in the individual who has
Siglec-16. Siglec-11 might have contributed to the
human brain evolution by its neuroprotective effect via
inhibition of unnecessary activation of microglia. Further
investigation would be needed to examine the evolution-
ary role of dimorphism of Siglec-11/Siglec-16 paired
receptors.
Conclusions
Siglec-11 and Siglec-16 are inhibitory and activating re-
ceptors, respectively, and expressed in the same cells
such as macrophages [8, 9]. Similar glycan binding pref-
erences between Siglec-11 and Siglec-16 have been
maintained by sequence homogenization via gene con-
version in each primate lineage. Thus, Siglec-11 and
Siglec-16 are regarded as paired receptors, and repeated
gene conversions have played an important role in the
evolution of Siglec-11/Siglec-16 paired receptors in the
primate lineage. The relaxed functional constraint on
the exons of the converted regions of both SIGLEC11
and SIGLEC16 genes seems to have contributed to the
maintenance of Siglec-11 and Siglec-16 as paired recep-
tors by the acceptance of repeated gene conversions.
The high prevalence of the nonfunctional SIGLEC16P
allele and the fixation of the converted SIGLEC11 in
human populations imply that the dimorphism of
Siglec-11/Siglec-16 paired receptors, namely, Siglec-11/
Siglec-16 and Siglec-11/Siglec-16P, have been main-
tained under some evolutionary constraint in the human
lineage.
Methods
Sequences of SIGLEC11 and SIGLEC16 genes
The human SIGLEC11 and SIGLEC16 genes show
sequence similarity in the ~3-kb region containing a
region upstream of the gene and the first eight exons
[8, 10, 11]. We targeted these similar genomic regions
(target regions) in this study. In the public databases,
the complete genomic sequences of target regions of
both the SIGLEC11 gene and the SIGLEC16 gene are
available from the human (Homo sapiens), the chim-
panzee (Pan troglodytes), and the baboon (Papio anu-
bis). However, the target regions of the SIGLEC16 gene
are incomplete in the public databases of other ape ge-
nomes. We thus obtained the complete sequences from
the gorilla (Gorilla gorilla) and the gibbon (Hylobates
lar) by using genomic PCR (GenBank accession nos.
LC194903–194906). In addition to these two primates,
human and chimpanzee sequences were also amplified
for the construction of expression vectors of glycan
binding assays (see the section on the preparation of re-
combinant Siglec fusion protein). Human genomic DNA
was purchased at Coriell Cell Repositories, and ape
genomic DNA samples were provided from Max Planck
Institute for Biology. The PCR primers (HS11F0, HS11R0,
HS11R0G, HS16F1, HS16R2, and HS16R2G; see
Additional file 7: Table S2) were designed based on the
genomic sequences of the human, chimpanzee, and gorilla
in the public database (http://www.ncbi.nlm.nih.gov). PCR
reactions were performed with 20 pmol of each primer
and 2–5 μl of the genomic DNA solution in a total volume
of 50 μl containing 200 μM dNTPs and 2.5 units of EX-
Taq DNA polymerase (Takara, Otsu, Japan) in PCR buffer
containing 2 mM MgCl2. The PCR conditions were as fol-
lows: denaturation at 95°C for 5 min; followed by 40 cycles
of 95°C for 1 min, 60–68°C for 1 min, and 72°C for 5 min;
and final extension at 72°C for 10 min. As for the gorilla,
nested PCR using primers (GS11F3, GS11R3, GS16F2,
and GS16R2; see Additional file 7: Table S2) was per-
formed to obtain a sufficient amount of PCR products for
sequencing and vector construction for the glycan binding
assay. The conditions of nested PCR were as follows: de-
naturation at 95°C for 5 min; followed by 35 cycles of 95°
C for 1 min, 62°C for 1 min, and 72°C for 5 min; and final
extension at 72°C for 10 min. The obtained PCR products
were purified using the QIAquick PCR Purification Kit
(Qiagen) and directly sequenced on an ABI 3130 genetic
analyzer (Applied Biosystems, Foster City, CA).
Sequences of target regions of baboon SIGLEC11 and
SIGLEC16 genes were obtained from the baboon
genome sequences (Baylor Panu_2.0/papAnu2; UCSC
Genome Browser, http://genome.ucsc.edu/cgi-bin/hgGa-
teway). We also obtained the sequence of the SIGLEC11
gene from the marmoset (Callithrix jacchus) genome
database (WUGSC 3.2/caljac3; UCSC Genome Browser,
http://genome.ucsc.edu/cgi-bin/hgGateway).
Sequence analysis
DNASIS software (Hitachi, Tokyo, Japan) was used to as-
semble sequences. Phylogenetic tree construction was per-
formed by the neighbor-joining method with multiple-hit
corrections using MEGA5 software [22–24]. DnaSP ver-
sion 3 [25] was used to obtain a sliding window plot repre-
senting the nucleotide differences.
To examine functional constraints on the exons in
genomic regions that underwent gene conversion,
lineage-specific ratios of nonsynonymous substitutions
per site and neutral substitutions per site were exam-
ined. In this analysis, intronic sites and synonymous sites
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were used to estimate neutral substitution. A phylogen-
etic tree of introns was constructed, and its tree top-
ology was used as a reference. Based on this reference
tree topology, the number of substitutions of every
branch was estimated for synonymous sites and nonsy-
nonymous sites, separately, by using the least squares
method. Neutral substitutions per site for each lineage
were obtained from the average of synonymous substitu-
tions per site and intronic substitutions per site. Z-tests
were performed to examine the significance of differ-
ences in lineage-specific ratios of nonsynonymous sub-
stitutions per site to neutral substitutions per site.
Preparation of recombinant Siglec-11-Fc and Siglec-16-Fc
fusion proteins
Recombinant proteins, consisting of the “immunoglobu-
lin-like domains 1 + 2” of Siglec-11 or Siglec-16 of
human, chimpanzee, and gorilla and the “hinge + Fc” re-
gion of human IgG, were prepared as follows.
The genomic DNA segments encompassing exons 1
through 4 of the SIGLEC11 gene or the SIGLEC16 gene
of respective species (approx. 1.3 kb) were amplified by
using appropriate genomic DNA templates and primer
pairs (Additional file 8: Table S3), using Phusion High-
Fidelity DNA Polymerase (Finnzymes/Thermo Scien-
tific). Amplified DNA fragments were digested with Xba
I (New England Biolabs) and cloned into Xba I–EcoRV
sites of the AvT-EK-Fc/pcDNA vector [26], and the se-
quences of the resulting constructs were confirmed. As
the yields of recombinant proteins produced by using
these constructs were generally poor (data not shown),
removal of introns from the Siglec-coding segments was
carried out as follows.
The 293T human embryonic kidney cell line was tran-
siently transfected with the constructs prepared as above
using LipofectAMINE 2000 (Life Technologies), and the
total RNA was prepared from each transfectant using
RNeasy Mini Kit (Qiagen). The RNA samples (1 μg
each) were reverse-transcribed and subjected to PCR
using Phusion DNA polymerase and the same primer
pairs as employed for the amplification of respective
genomic DNA fragments. The resulting PCR products
were purified, subcloned to Xba I–EcoRV sites of the
AvT-EK-Fc/pcDNA vector, and the sequences of the
resulting constructs were confirmed. These expression
constructs were given systematically named using the
three-letter abbreviation of the systematic name of the
species of origin and the Siglec number (i.e., Hsa Siglec-
11 or 16-Fc/pcDNA, Ptr Siglec-11 or 16-Fc/pcDNA, and
Ggo Siglec-11 or 16-Fc/pcDNA).
Production and purification of Siglec-Fc fusion pro-
teins were carried out as previously described [17, 27].
In short, 293T cells (or 293A cells) were transiently
transfected with the recombinant protein expression
constructs using LipofectAMINE 2000. The culture
medium was switched to 2% low IgG fetal bovine serum
(HyClone/Thermo Scientific) in Opti-MEM (Life Tech-
nologies) the next day, and the culture supernatant was
collected on third and sixth days after changing medium.
Recombinant Siglec-Fc proteins were purified from the
combined culture supernatant by adsorption to Protein
A Sepharose (GE Healthcare Life Sciences), with on-
column treatment with Arthrobacter ureafaciens sialid-
ase to remove sialic acids from the Siglec-Fc proteins
themselves, and used for binding assays.
Analysis of binding between synthetic glycan probes and
Siglec-Fc
Analysis of the binding between glycan probes and
Siglec-Fc was performed as described previously [27],
with minor modifications. In brief, soluble protein A (0.5
μg/well; Sigma-Aldrich) was immobilized onto a 96-well
plate (#269620, Corning) by overnight incubation in al-
kaline buffer (50 mM sodium bicarbonate buffer, pH 9.5)
at 4°C. In the subsequent steps, incubations were carried
out at room temperature (RT), and the wells were
washed three times with 1% bovine serum albumin in
Dulbecco’s phosphate-buffered saline (blocking buffer)
in-between incubations with different reagents. The
wells were blocked with blocking buffer for 1 h, and
Siglec-Fc proteins (0.5 μg/well) were adsorbed to the
wells for 3 h. The wells were further incubated with bio-
tinylated polyacrylamide-based probes carrying multiple
copies of synthetic oligosaccharides (glycan probes, 0.5
μg/well; GlycoTech) for 2 h. Each combination of recom-
binant protein and probe was tested in triplicate wells.
The wells were further incubated with streptavidin-
conjugated alkaline phosphatase (1 μg/well; Jackson
ImmunoResearch) for 2 h, followed by incubation with
alkaline phosphatase substrate solution (10 mM p-nitro-
phenyl phosphate, 1 mM MgCl2, 100 mM Na2CO3).
Absorption at 405 nm was monitored with a microplate
reader (VersaMax, Molecular Devices) at different time
points up to 60 min.
Analysis of Siglec-Fc binding to glycan microarray
Glycan microarrays were fabricated as described previ-
ously (array 1; [28]). Each glycan was represented by
four spots per subarray in 100 μM in an optimized print
buffer (300 mM phosphate buffer, pH 8.4). Printed gly-
can microarray slides were blocked by ethanolamine,
washed, and dried. Slides were then fitted in a multi-well
microarray hybridization cassette (AHC4X8S; ArrayIt,
Sunnyvale, CA, USA) for division into eight subarrays
(each subarray comprising the complete set of glycans).
The subarrays were blocked with ovalbumin (1% w/v) in
PBS (pH 7.4) for 1 h at RT, with gentle shaking. Subse-
quently, the blocking solution was removed and Siglec-
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Fc (400 μl, at 20 or 40 μg/ml) was applied to each subar-
ray. After incubating the samples for 2 h at RT with
gentle shaking, the slides were washed. Diluted goat
anti-human IgG-Cy3 antibody (Jackson ImmunoRe-
search Laboratories) in PBS was added to the subarrays,
incubated for 1 h at RT, washed, and dried. The micro-
array slides were scanned by a Genepix 4000B micro-
array scanner (Molecular Devices Corp., Union City,
CA, USA). Data analysis was performed using Genepix
Pro 7.0 analysis software (Molecular Devices Corp.), and
Siglec-Fc binding to each glycan was quantified as the
relative fluorescence intensity (RFU) of spots by subtrac-
tion of the background and averaging of four spots for
the same glycan.
Cluster analysis of glycan microarray data
Cluster analysis of glycan microarray data was conducted
by using R (version 3.1.1, https://www.R-project.org), with
add-on packages. Binding data in RFU were normalized
by the root mean square method. The unsupervised hier-
archical clustering of Siglecs and glycans was performed
by a complete linkage method with the hclust function, in
which a dissimilarity structure was calculated by using
Euclidean distance.
Additional files
Additional file 1: Figure S1. Alignment of genomic nucleotide
sequences of SIGLEC11 and SIGLEC16 in human, chimpanzee, gorilla,
gibbon, baboon, and marmoset. The genomic region of human SIGLEC11
including the first eight exons is aligned with the corresponding regions
of SIGLEC11 and SIGLEC16 from other primates. Dots indicate nucleotides
identical to those of human SIGLEC11. Dashes indicate gaps used for
sequence alignment. Exons are marked with the red bars lying on the
sequences. Red open box indicates the ATG start codon. The arrows
indicate the boundaries of A/A’ and B/B’ regions (see also Figure 1B). The
putative GATA-1-binding sequence is underlined. The SIGLEC16P
sequence is represented as human sequence of SIGLEC16 gene because
of the SIGLEC16P→SIGLEC11 gene conversion in the human lineage [10,
11]. Hsa, Homo sapiens; Ptr, Pan troglodytes; Ggo, Gorilla gorilla; Hla,
Hylobates lar; Pan, Papio anubis; Cja, Callithrix jacchus. (PDF 2906 kb)
Additional file 2: Figure S2. Phylogenetic relationships of the A/A’
regions of SIGLEC11 and SIGLEC16. The partial sequence of bonobo
SIGLEC11 was obtained previously (GenBank accession no. AB211392; [11])
and used in the tree construction. The tree topology is identical to that
shown in Fig. 2A, with the exception of genes of the genus Pan. As for
the lineage of the genus Pan, bonobo SIGLEC11 is most closely related to
chimpanzee SIGLEC11 but the genes of genus Pan form a cluster in the
tree. This suggests that gene conversion between SIGLEC11 and SIGLEC16
occurred before the divergence of chimpanzee and bonobo in the
lineage of the genus Pan. Numbers on the phylogenetic tree represent
bootstrap values based on 1000 replications. Hsa, Homo sapiens; Ptr, Pan
troglodytes; Ppa, Pan paniscus; Ggo, Gorilla gorilla; Hla, Hylobates lar; Pan,
Papio anubis; Cja, Callithrix jacchus. (PDF 45 kb)
Additional file 3: Figure S3. Alignment of amino acid sequences of
Siglec-11 and Siglec-16 proteins in primates. Amino acid sequences of
primate Siglec-11 and Siglec-16 (signal peptide + first and second
immunoglobulin-like domains) were aligned by ClustalO. The amino acid
position fully conserved among all aligned Siglec-11 and Siglec-16 is
marked with asterisk (*), and the position conserved within groups of
strongly or weakly similar amino acids (based on the properties of side
chain) is marked with colon (:) or period (.), respectively. Functional human
Siglec-16 sequence was used for the alignment. Hsa: Homo sapiens; Ptr: Pan
troglodytes; Ggo: Gorilla gorilla; Hla: Hylobates lar; Pan: Papio anubis; Cja:
Callithrix jacchus. Residues important for sialic acid recognition are marked
with colored squares. Because the atomic level structure of Siglec-11/-16 is
not available at present, amino acid residues known to be important for
glycan recognition by Siglecs in common (based on the atomic level
structures of Siglec-1, -2, -4, -5, and -7 in complex with respective ligand) are
indicated. Red square: essential arginine residue interacting with the
carboxyl group of sialic acid; Orange squares: aromatic amino acid residues
involved in the coordination of sialic acid. (PDF 36 kb)
Additional file 4: Figure S4. Relaxed evolution of exons that
underwent gene conversions. The phylogenetic tree of introns was used
as a reference to examine functional constraints. The topology of the
intron tree is similar to that of the Ac/Ac’ region, representing that gene
conversion occurred in each primate lineage (Figure 2A). Lineage-specific
ratios of nonsynonymous substitutions per site to silent substitutions per
site (at both synonymous and intron sites) are shown on each branch. A
significant difference between nonsynonymous substitutions per site and
neutral substitutions per site is found in only three branches, one leading to
gorilla SIGLEC11, one leading to baboon SIGLEC11, and the other leading to
two baboon genes (P<0.02, Z-test). These branches are represented by bold
lines. Hsa, Homo sapiens; Ptr, Pan troglodytes; Ggo, Gorilla gorilla; Hla,
Hylobates lar; Pan, Papio anubis; Cja, Callithrix jacchus. (PDF 40 kb)
Additional file 5: Figure S5. Distribution of SIGLEC16 and SIGLEC16P
alleles in human populations. Pie charts represent the proportion of each
allele type by geographic regions. The frequencies at rs12984584 are
used as a representative in this figure. 1, Americans of African ancestry
(USA); 2, Gambian in Western Divisions (The Gambia); 3, Mende (Sierra
Leone); 4, Esan (Nigeria); 5, Yoruba in Ibadan (Nigeria); 6, Luhya in
Webuye (Kenya); 7, Utah residents (CEPH) with Northern and Western
European ancestry; 8, Finnish (Finland); 9, British in England and Scotland;
10, Iberian population (Spain); 11, Tuscans (Italy); 12, Punjabi from Lahore
(Pakistan); 13, Gujarati Indian from Houston (USA); 14, Indian Telugu from
the UK; 15, Sri Lankan Tamil from the UK; 16, Bengali (Bangladesh); 17,
Han Chinese in Bejing (China); 18, Southern Han Chinese (China); 19,
Chinese Dai in Xishuangbanna (China); 20, Kinh in Ho Chi Minh City
(Vietnam); 21, Japanese in Tokyo (Japan); 22, Mexican ancestry from Los
Angeles (USA); 23, Puerto Ricans (Puerto Rico); 24, African Caribbeans
(Barbados); 25, Colombians from Medellin (Colombia); and 26, Peruvians
from Lima (Peru). Original genotyping data were obtained from the
website of the 1000 Genomes Project (http://browser.1000genomes.org/
index.html). (PDF 463 kb)
Additional file 6: Table S1. Frequencies of SIGLEC16 and SIGLEC16P in
human populations. (XLSX 18 kb)
Additional file 7: Table S2. Primer sequences for genomic PCR. (XLSX 9 kb)
Additional file 8: Table S3. Primer sequences for preparation of
recombinant proteins. (XLSX 9 kb)
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